Novonesis (NSIS) AGM 2023 summary
Event summary combining transcript, slides, and related documents.
AGM 2023 summary
26 Oct, 2026Board and executive committee updates
Cornelis (Cees) de Jong was elected Chair and Kim Stratton Vice Chair; Heine Dalsgaard, Sharon James, Kasim Kutay and Morten Sommer were re-elected as directors.
Following the AGM, the Board also included employee representatives Anne Breum, Anders Hentze Knudsen, Preben Nielsen and Jens Øbro.
Dividend announcements
Profit distribution for FY2022 included a dividend of DKK 6.00 per DKK 2 share, up 9% compared with 2021.
Corporate governance
Shareholders approved the 2022 remuneration report and remuneration for Board members.
PricewaterhouseCoopers was re-elected as auditor; authorizations for capital increases, treasury-share acquisitions and extraordinary dividends were renewed or approved.
Amendments to the articles of association and remuneration policy were approved regarding indemnification of Board members and executive management.
Latest events from Novonesis
- 9M organic growth reached 7% and margin 37.9%; Human Health weakness and investment weighed.NSIS
Q3 2026 - FY2020 report approved; DKK 5.25 dividend retained and Board leadership re-elected.NSIS
AGM 2021 - 2021 report approved; dividend rose 5%, and Morten Sommer joined the Board.NSIS
AGM 2022 - Shareholders approved a secondary name and elected four Board leaders.NSIS
EGM 2024 - Raised full-year sales growth outlook to 7-8% after 8% organic growth and EUR 1bn buyback.NSIS
Q2 2026 - Strong 2024 results; shareholders approved the dividend, elections, and key authorizations.NSIS
AGM 2025 - Diversification and innovation support biofuel growth and emerging SAF opportunities.NSIS
Status Update - 2024 outlook upgraded with higher growth and margins, driven by innovation and synergies.NSIS
CMD 2024 - 11% organic sales growth, margin expansion, and a major acquisition highlight Q1 2025.NSIS
Q1 2025